Cocrystal Pharma (COCP) Share-based Compensation (2011 - 2026)
Cocrystal Pharma (COCP) reported Share-based Compensation of $84000.0 for Q1 2026, up 2.44% on a YoY basis from $82000.0 in Q1 2025, and up 50.0% sequentially from $56000.0 in Q4 2025.
Cocrystal Pharma (COCP) Share-based Compensation (2011 - 2026) Analysis & Trends
Cocrystal Pharma (COCP) has 14 years of Share-based Compensation data on file, last reported at $84000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 2.44% year-over-year to $84000.0; the trailing twelve-month figure through Mar 2026 stood at $307000.0 (down 47.52% YoY), and the FY2025 full-year result was $270000.0, down 58.01% from the prior year.
- Share-based Compensation advanced to $84000.0 in Q1 2026, from $56000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $643000.0 in Q3 2022 to a low of $56000.0 in Q4 2025.
- A 5-year average of $208823.5 and a median of $159000.0 in 2022 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation surged 213.66% in 2022 and sank 65.87% in 2025, its largest moves.
- Tracing COCP's Share-based Compensation over 5 years: stood at $159000.0 in 2022, then fell by 0.63% to $158000.0 in 2023, then tumbled by 46.2% to $85000.0 in 2024, then tumbled by 34.12% to $56000.0 in 2025, then jumped by 50.0% to $84000.0 in 2026.
- Business Quant data shows COCP's Share-based Compensation at $84000.0 in Q1 2026, $56000.0 in Q4 2025, and $86000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 305,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 87.30 Mn |
| 10 | Cocrystal Pharma | 12.57 Mn | 7.74 Mn | - | 84,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Dec 31, 2025 | 56,000.00 |
| Dec 31, 2025 | 56,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 166,000.00 |
| Jun 30, 2024 | 166,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Dec 31, 2023 | 158,000.00 |
| Dec 31, 2023 | 158,000.00 |